Swiss drugmaker Roche has revealed that latest studies indicate Avastin may be helpful in lung cancer patients when given in combination with gemcitabine-cisplatin chemotherapy
The study showed that such a combination extended the time patients are able to survive without lung cancer progression. The "Avail" trial found that patients with advanced non-small cell lung cancer (NSCLC) were able to live 30 percent longer without disease progression when Avastin was given in combination with other drugs.
"Avail confirms for the second time that Avastin provides important clinical benefits and the longest survival reported for patients with advanced non-squamous NSCLC," said principal investigator Christian Manegold of Heidelberg University in Mannheim, Germany.
The details of the study were presented at the European Society of Medical Oncology in Stockholm.